Credit: Getty Images Researchers assessed patients with uncomplicated urinary tract infections to determine factors associated with extended-spectrum β-lactamase-producing uropathogens.

Exblifep is a combination product that consists of cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor. The Food and Drug Administration (FDA) has approved Exblifep ...

An international study led by a Rutgers scientist comparing new and older treatments against complicated urinary tract infections has found a new drug combination to be more effective, especially ...

When it comes to treating urinary tract infections (UTIs), antibiotics continue to be the number one go-to treatment. Most ...

Extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) have become a critical global public health challenge due to their high resistance to β-lactam antibiotics and association with severe ...

An international study led by a Rutgers scientist comparing new and older treatments against complicated urinary tract infections has found a new drug combination to be more effective, especially ...

Credit: Getty Images. The Infectious Diseases Society of America aimed to develop up-to-date guidance focusing on the treatment of antimicrobial-resistant gram-negative infections. The Infectious ...

Compared with meropenem, cefepime-taniborbactam is superior for microbiologic and clinical cure of complicated urinary tract infection, including acute pyelonephritis. Cefepime-taniborbactam is more ...

In most prospective studies patients with diabetes are characterised as having 'complicated infections'. However, categorising all patients with diabetes into this group trivialises the concept. Many ...

The Biomedical Advanced Research and Development Authority (BARDA) in the US will support Basilea’s development of a new type of oral antibiotic to treat complicated urinary tract infections (cUTIs).